Intelligent Bio Solutions, Inc.

As of October 15, 2023, Intelligent Bio Solutions, Inc. is considered attractive and undervalued, with a P/E ratio of 12.5 and a P/B ratio of 1.8, outperforming peers and the Sensex, indicating the market may not fully recognize its growth potential.

As of October 1, 2023, there is insufficient technical data for Intelligent Bio Solutions, Inc. to determine a bullish or bearish outlook.

Intelligent Bio Solutions, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $1 million and a net loss of $3 million as of March 2025. Key financial metrics include a market cap of $13.34 million, a P/E ratio of NA, and a return on equity of -201.38%.

As of Jun 18, Intelligent Bio Solutions, Inc. has a market capitalization of 13.34 million, with net sales of 2.94 million and a net profit of -10.30 million over the latest four quarters. Shareholder's funds are 8.33 million, and total assets are 13.78 million as of Jun 24.